

Supplemental Information

Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox

Target	Non-MNA cell lines			MNA cell lines						Hits (viability)		Correlation with MYCN	
	SK-N-SH	SK-N-AS	CHLA20	NB-1643	BE(2)-C	NB7	NB15	Nagai	NB-1691	Reduce	Increase	R	p value
C14orf169	-0.23	-0.15	-0.03	-0.20	-0.13	-0.13	-0.24	-0.21	-0.38	4	0	0.286	0.0069
HIF1AN	-0.14	-0.23	0.03	-0.11	0.06	-0.30	-0.30	-0.17	-0.18	3	0	-0.113	0.3
HR	-0.27	0.03	-0.01	-0.33	-0.12	-0.26	0.03	-0.12	-0.26	4	0	0.102	0.35
HSPBAP1	-0.32	-0.49	0.18	-0.26	-0.11	-0.07	0.15	-0.31	-0.21	5	0	0.132	0.22
JARID2	-0.28	-0.12	0.03	-0.07	-0.13	-0.14	-0.02	-0.29	-0.26	3	0	-0.045	0.68
JHDM1D	-0.22	0.04	0.09	-0.07	-0.09	0.02	0.11	-0.16	-0.04	1	0	-0.141	0.19
JMJD1C	-0.06	0.28	0.12	-0.02	0.36	0.15	0.10	-0.11	-0.10	2	0	0.195	0.07
JMJD4	-0.19	-0.18	0.08	0.01	-0.16	0.16	0.19	-0.22	-0.04	1	0	0.224	0.02
JMJD6	-0.15	-0.29	0.29	0.01	-0.47	-0.52	-0.57	-0.27	-0.20	6	1	0.274	0.0099
JMJD7	-0.18	-0.03	0.01	-0.07	-0.03	-0.11	-0.18	-0.20	-0.07	0	0	-0.198	0.06
JMJD8	-0.15	0.27	0.29	-0.14	0.11	0.02	0.01	-0.02	-0.01	1	1	0.281	0.0081
KDM1A	-0.10	-0.22	0.12	-0.21	0.01	-0.50	-0.04	0.05	-0.12	3	0	-0.034	0.75
KDM1B	-0.18	0.26	0.14	-0.10	-0.02	-0.01	-0.23	-0.04	-0.07	1	1	-0.028	0.79
KDM2A	0.06	0.07	0.27	0.03	0.12	-0.25	-0.01	-0.24	-0.12	2	1	-0.021	0.85
KDM2B	-0.43	-0.37	-0.21	-0.14	-0.17	-0.09	-0.02	-0.28	-0.30	5	0	0.216	0.04
KDM3A	-0.11	-0.23	0.06	-0.10	0.29	0.06	0.36	-0.08	-0.05	1	2	0.315	0.0028
KDM3B	0.11	-0.37	0.34	0.06	-0.49	-0.62	-0.06	-0.12	-0.16	3	1	-0.01	0.92
KDM4A	-0.10	-0.16	0.08	-0.17	-0.01	-0.56	-0.27	-0.15	-0.18	2	0	-0.217	0.04
KDM4B	-0.27	0.02	0.06	-0.21	-0.24	-0.32	-0.30	-0.28	-0.32	7	0	0.385	0.00021
KDM4C	-0.01	-0.16	0.09	-0.17	0.12	0.11	0.20	-0.13	-0.16	0	1	-0.312	0.0031
KDM4D	-0.30	-0.44	0.11	-0.07	-0.26	-0.35	-0.16	-0.12	-0.33	5	0	0.249	0.02
KDM4E	-0.45	-0.41	-0.03	-0.28	-0.10	-0.36	-0.41	-0.22	-0.36	7	0	N/A	N/A
KDM5A	-0.13	-0.19	-0.03	-0.17	-0.33	-0.19	0.06	-0.19	-0.18	1	0	0.171	0.11
KDM5B	-0.31	-0.14	0.06	-0.22	0.00	-0.14	-0.02	-0.10	-0.21	3	0	0.357	0.00064
KDM5C	-0.15	-0.51	-0.06	-0.18	0.00	-0.43	-0.13	-0.23	-0.41	4	0	0.299	0.0047
KDM5D	-0.12	-0.19	0.10	-0.14	-0.11	-0.17	0.06	-0.28	-0.01	1	0	0.011	0.92
KDM6A	0.14	0.25	0.14	-0.04	-0.32	0.06	-0.12	-0.11	-0.17	1	1	0.07	0.52
KDM6B	-0.52	-0.34	-0.06	-0.18	-0.18	-0.30	-0.31	-0.23	-0.15	5	0	0.231	0.03
KDM8	-0.35	0.06	0.11	0.01	-0.09	-0.24	-0.17	-0.19	-0.19	2	0	0.146	0.17
MINA	-0.04	-0.18	0.20	-0.23	0.16	-0.05	0.04	-0.03	-0.11	1	1	0.193	0.07
PHF2	-0.23	-0.35	0.09	-0.13	0.02	-0.30	-0.24	-0.24	-0.05	5	0	0.129	0.23
PHF8	0.09	0.09	0.21	-0.08	-0.12	0.02	-0.28	-0.23	-0.08	2	1	0.173	0.11
TYW5	-0.13	0.08	0.10	0.01	-0.08	-0.09	-0.02	-0.25	-0.22	2	0	0.061	0.57
UTY	-0.13	0.22	0.21	-0.21	-0.03	-0.21	-0.05	-0.26	-0.17	3	2	0.043	0.69

Figure S1. siRNA screening in neuroblastoma cells.

Cell viability assessment after siRNA knockdown of histone demethylases and genes encoding MjC domain containing non-histone demethylase proteins. The first nine columns represent the value of each gene subtracted by 1 after being normalized to the control. The viability threshold is set to (+0.2, -0.2). A value of less than -0.2 defined the genes that reduced cell viability. A value of greater than 0.2 defined the genes that increased cell viability. MNA = MYCN amplification. The green rows indicate siRNA knockdown reduced proliferation in at least 4 cell lines. HR and HSPBAP1, two genes without histone demethylase activity were highlighted in the grey rows.




Figure S2. Identification of ciclopirox that targets KDM4B

(A) CMAP analysis to identify small molecules that generate a transcriptome inversely matching the KDM4B knockdown. The rank, name, mean connectivity score, the number of instances (n), enrichment of those instances in the order list of all instances, a permutation p-value for that enrichment score (P), the specificity of that enrichment (specificity), and the non-null percentage are shown in the table. (B) A similar strategy was used to identify small molecules that generate a transcriptome inversely matching the advanced neuroblastoma signature. The neuroblastoma gene expression profile (GSE12460, Janoueix-Lerosey et al) was reanalyzed according to INSS stage.

The top differential genes were used to perform CMAP. **(C)** Immunofluorescence shows a global change of H3K9me3/me2/me1 marks after overexpression of HA-tagged KDM4B in SK-N-AS cells (left). 5.0 μ M of CPX treatment for 48 hours blocked erasure of H3K9me3 by HA-KDM4B (right). Arrows indicate the cells overexpressing HA-KDM4B. **(D)** U2OS parental and U2OS-KDM4B were treated with different concentrations of CPX. Positive H3K9me3 cells were quantified by immunofluorescence. **(E)** Structures of CPX and HDAC inhibitors. **(F)** NB-1691 cells were treated with 5 μ M of CPX and 2.5 μ M of vorinostat for the indicated duration. Western blotting was used to assess acetylated tubulin and histone H3.




Figure S3. CPX effect on other histone methyl marks

(A-B) Different concentrations of CPX were used to treat NB-1691 and BE(2)-C cells for 48 hours. Whole cell lysates from samples as shown in Figure 2B were subject to western blotting with indicated antibodies. (C-G) 293T cells were transfected with expression constructs for the indicated

histone demethylases. 8 hours after transfection, cells were treated with 5.0 μ M of CPX and/or 500 μ g/ml of holo-transferrin that carries iron into cells, for 24 hours. Western blotting was used to assess the indicated markers. (H) CPX induces a similar expression profile as JIB-04. GSEA analysis of the JIB-04 signatures (downregulated and upregulated) with the CPX expression profile.

A

GSEA for enrichment of CPX targets (Genetic and chemical perturbations)

NAME	NES	NOM p-val	FDR q-val
SCHUHMACHER_MYC_TARGETS_UP	2.1	0	0.001
JYANG_MYCN	2.0602424	0	0.001740632
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP	1.9022601	0	0.009949825
MENSSSEN_MYC_TARGETS	1.8271015	0	0.020422729
SANSOM_APC_TARGETS_REQUIRE_MYC	1.826927	0	0.019973619
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN	1.7787449	0	0.028089175
SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM	1.7770976	0	0.028022494
KIM_MYC_AMPLIFICATION_TARGETS_UP	1.6246115	0	0.077343486
DANG_MYC_TARGETS_UP	1.6043347	0	0.0859786
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN	1.707464	0.0019724	0.04636353
DANG_REGULATED_BY_MYC_UP	1.5659686	0.0019763	0.10390965
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP	1.709521	0.0041929	0.045992367
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_UP	1.6639152	0.0056711	0.063507766
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY	1.7851715	0.0084211	0.026890123
BILD_MYC_ONCOGENIC_SIGNATURE	1.3102815	0.0293542	0.3030681
KIM_MYCL1_AMPLIFICATION_TARGETS_DN	1.4097298	0.0658436	0.2076127

B

GSEA for enrichment of CPX targets (Oncogenic signatures)

NAME	NES	NOM p-val	FDR q-val
MYC_UP.V1_UP	2.0591497	0	0
EIF4E_UP	1.6493754	0.004056795	0.02482508
CSR_LATE_UP.V1_UP	1.6395335	0	0.018402291
RPS14_DN.V1_DN	1.6152741	0	0.017571498
GCNP_SHH_UP_LATE.V1_UP	1.4219851	0.004210526	0.10633502
STK33_NOMO_DN	1.3973626	0	0.11529338
STK33_DN	1.3874437	0.001976285	0.10959221
BMI1_DN.V1_DN	1.3646958	0.030181086	0.122080706
RB_P107_DN.V1_UP	1.3415922	0.029350106	0.13575825

C

GSEA for enrichment of CPX targets (Transcription factor binding motif)

NAME	NES	NOM p-val	FDR q-val
V\$MYC_MAX_01	1.74	0	0.056
TMTCGCGANR_UNKNOWN	1.57	0	0.253
GKCGCNNNNNNTGAYG_UNKNOWN	1.46	0	0.478
V\$USF_C	1.45	0	0.429
V\$USF_Q6_01	1.41	0	0.477
V\$NFMUE1_Q6	1.39	0.022	0.513
V\$ZF5_B	1.39	0	0.441
V\$USF_Q6	1.3	0.019	0.841
V\$MYC_MAX_B	1.3	0.042	0.81

D




Figure S4. CPX targets the Myc pathway

(A) Gene set (from genetic and chemical perturbations) representing Myc pathways or signatures that are enriched with CPX targets, as analyzed by GSEA. NES = Normalized enrichment score. NOM = normalized. FDR = false discovery rate. (B) Gene set (oncogenic signatures) enrichment analysis for CPX targets. (C) Gene set (transcription factor binding motif signatures) enrichment analysis for CPX targets. (D) Heat map analysis of occupancy peaks of H3K9me3, c-Myc and KDM4A in human embryonic stem cells (ENCODE data).





Figure S5. CPX inhibits oxidative phosphorylation


(A-C) GSEA analysis of our microarray data reveals that CPX suppresses genes involved in oxidative phosphorylation or electron transport chain reaction. (D) After treating NB-1691 cells for 48h with 2.5 μ M CPX, RT-PCR was used to validate the genes involved in mitochondria respiration. (E) Oxygen consumption analysis showing consumption was compromised by CPX treatment of NB-1691 cells for 48 hours. (F) Oxygen consumption was compromised by depletion

of KDM4B in NB-1691 cells. (G) Oxygen consumption was also compromised by depletion of MYCN in NB-1691 cells.

A



B



C




Figure S6. CPX effect on BE2C xenografts with KDM4B knockdown

(A) Growth of BE2(C) subcutaneous xenografts, shRNA control (n=5/group) and KDM4B knockdown (n=5/group). P value was computed by Student's t test.

(B-C) shRNA-ctrl and shKDM4B tumor bearing mice were treated with vehicle or 20 mg/kg of CPX twice daily via oral gavage. Kaplan-Meier analysis of survival curve with the Wilcoxon test

being used to determine the P value for shRNA control (n=5/group) (**B**) or shKDM4B-814 group (n=5/group) (**C**).

Table S1. The sequences of the focused KDM siRNA library

Plate 1	C05	M-022873-01	D-022873-01	JMJD8	339123	NM_001005920	56090145	CGUAAGCGCUGGUUCCUUU
Plate 1	C05	M-022873-01	D-022873-02	JMJD8	339123	NM_001005920	56090145	CGAGUGGGCCUCUCUCUUU
Plate 1	C05	M-022873-01	D-022873-04	JMJD8	339123	NM_001005920	56090145	GGUACUCAGAAUGUAUCUA
Plate 1	C05	M-022873-01	D-022873-17	JMJD8	339123	NM_001005920	56090145	CCAGUAAAGCUCUUGAAUA
Plate 1	C06	M-025357-01	D-025357-02	JHDM1D	80853	NM_030647	90093354	GCACAGACUAGACACACA
Plate 1	C06	M-025357-01	D-025357-03	JHDM1D	80853	NM_030647	90093354	GAUACCAUGUCAAACUGA
Plate 1	C06	M-025357-01	D-025357-04	JHDM1D	80853	NM_030647	90093354	GGAAACUUCGAGAUCAUA
Plate 1	C06	M-025357-01	D-025357-17	JHDM1D	80853	NM_030647	90093354	CUAAUAAACACCCGUGUAA
Plate 1	C07	M-009223-01	D-009223-01	KDM1A	23028	NM_015013	58761545	UGAAUUAGCUGAAACACAA
Plate 1	C07	M-009223-01	D-009223-02	KDM1A	23028	NM_015013	58761545	GACAAGCUGUUCUAAAGA
Plate 1	C07	M-009223-01	D-009223-03	KDM1A	23028	NM_015013	58761545	GUAAAGCCACCCAGAGUA
Plate 1	C07	M-009223-01	D-009223-04	KDM1A	23028	NM_015013	58761545	CUAAUAAAGCUCAAUACUG
Plate 1	C08	M-008121-01	D-008121-01	KDM1B	221656	NM_153042	116256450	CUGCAUAACUUUGGAAUUA
Plate 1	C08	M-008121-01	D-008121-02	KDM1B	221656	NM_153042	116256450	GGACCACAAUAAUUCUUU
Plate 1	C08	M-008121-01	D-008121-04	KDM1B	221656	NM_153042	116256450	UAACAACCCAGUAGCAUUA
Plate 1	C08	M-008121-01	D-008121-17	KDM1B	221656	NM_153042	116256450	GGUCAGUUUAAUACAGUA
Plate 1	C09	M-016031-01	D-016031-01	MINA	84864	NM_153182	110227620	GUACAUAAUCUCCCGCAGGA
Plate 1	C09	M-016031-01	D-016031-02	MINA	84864	NM_153182	110227620	GUAAGCAGAUAGAUUAGA
Plate 1	C09	M-016031-01	D-016031-03	MINA	84864	NM_153182	110227620	GGGCAACGUAUUCAGUUUCA
Plate 1	C09	M-016031-01	D-016031-17	MINA	84864	NM_153182	110227620	UCACAGUACUCCGGAUCA
Plate 1	C10	M-014397-01	D-014397-01	C14orf169	79697	NM_024644	106879205	GCGAAGAACCGCUUUC AUG
Plate 1	C10	M-014397-01	D-014397-02	C14orf169	79697	NM_024644	106879205	CCCGAGACUUAUGGAUUA
Plate 1	C10	M-014397-01	D-014397-03	C14orf169	79697	NM_024644	106879205	GUGCACCGCCCAACAUUA
Plate 1	C10	M-014397-01	D-014397-04	C14orf169	79697	NM_024644	106879205	GACCAGUCUCCUUGGC AA
Plate 1	C11	M-012912-01	D-012912-01	PHF2	5253	NM_005392	117190341	GCAAGCCUGACGUCGAAG
Plate 1	C11	M-012912-01	D-012912-02	PHF2	5253	NM_005392	117190341	AGGAGUUUGGACUUAUA
Plate 1	C11	M-012912-01	D-012912-03	PHF2	5253	NM_005392	117190341	ACGGGAAACUACUCCUUUA
Plate 1	C11	M-012912-01	D-012912-04	PHF2	5253	NM_005392	117190341	GCGCCGACAUCCACAUUA
Plate 1	D02	M-004291-00	D-004291-01	PHF8	23133	NM_015107	32698699	GAACCAAGAUAGCAAAGAA
Plate 1	D02	M-004291-00	D-004291-02	PHF8	23133	NM_015107	32698699	CAGCAGACCUUUCAGAUU
Plate 1	D02	M-004291-00	D-004291-03	PHF8	23133	NM_015107	32698699	GGAGGGAACUUCUACACA
Plate 1	D02	M-004291-00	D-004291-04	PHF8	23133	NM_015107	32698699	GGACAUUUUCCGCGUUUUG
Plate 1	D03	M-016468-01	D-016468-01	TYW5	129450	NM_001039693	89242133	GGUGAUGUAUUUAUUCUUC
Plate 1	D03	M-016468-01	D-016468-02	TYW5	129450	NM_001039693	89242133	GGACUUCUAUACACACGUA
Plate 1	D03	M-016468-01	D-016468-03	TYW5	129450	NM_001039693	89242133	CGAGAUCCAGUAUUUAUUA
Plate 1	D03	M-016468-01	D-016468-04	TYW5	129450	NM_001039693	89242133	CCGAGUUAUACAGAGGAUA
Plate 1	D04	M-014140-01	D-014140-01	KDM6A	7403	NM_021140	10863942	GAACAGUCCCGCCAAUA
Plate 1	D04	M-014140-01	D-014140-02	KDM6A	7403	NM_021140	10863942	GAGAGUAAUUCACGAAAGA
Plate 1	D04	M-014140-01	D-014140-04	KDM6A	7403	NM_021140	10863942	CAGCACGAAUUAAGUAUUU
Plate 1	D04	M-014140-01	D-014140-05	KDM6A	7403	NM_021140	10863942	GCUAAUUGGCUUGGCAACA
Plate 1	D05	M-017344-00	D-017344-01	UTY	7404	NM_007125	33188430	GCAAAUAGACACAAAGAA
Plate 1	D05	M-017344-00	D-017344-02	UTY	7404	NM_007125	33188430	GCUAGGCAGUAUUUGUAUA
Plate 1	D05	M-017344-00	D-017344-03	UTY	7404	NM_007125	33188430	CCAUGGAGAUUACCAAAUA
Plate 1	D05	M-017344-00	D-017344-04	UTY	7404	NM_007125	33188430	CAACUAGCACUGGUUAUUA

Table S2. Primers for Real time PCR

Primer Sequence	Gene Symbol	Forward or reverse
AACCCGTTGAACCCATT	18S	F
CCATCCAATCGGTAGTAGCG	18S	R
TGGCAAAGACTATTTGATTTTCA	ACADSB	F
GCAGCATTGTATGTTAGTAATCTTGC	ACADSB	R
AGGCACAGCGTTTCTTGC	ACN9	F
TTTGTTTCATCACGAAAGTCATTAAG	ACN9	R
CCAACCGCGAGAAGATGA	ACTIN	F
CCAGAGGCGTACAGGGATAG	ACTIN	R
GCCCACTATGCCCACTCTC	ANGPTL2	F
CTGCAGGCAGTCTCTCCAT	ANGPTL2	R
GAAGAAGAGGTGCCTGAGGA	ARID4A	F
CAGGTGGTTTGTGATTGGA	ARID4A	R
TCTGAGCCCGAACTGGAG	BOP1	F
TGCTGTGGCTGAGAGGAGA	BOP1	R
GCGAGCAGAGGCTTAAGGT	BTG2	F
GGGAAACCAGTGGTGTGTTGTA	BTG2	R
GAAGACCCCATCAAGGTG	CISD3	F
AAGAAGTGGGAGCCGTCAC	CISD3	R
TCAAGAGGTGCCACGTCTCC	CMYC	F
TCTTGGCAGCAGGATAGTCCTT	CMYC	R
TGCTCTTTGCCAACCAGA	CYB5R3	F
TGCAGAATGTTTGTTCCTGAGT	CYB5R3	R
GCCATGGTCAAGGGCTAC	DHCR7	F
TTGTAAAAGAAATTGCCTGTGAA	DHCR7	R
CGGAGCCTTCAGGGAAAG	DHODH	F
CACTCTCCGCAAGCCATC	DHODH	R
CACACTTCTCTCCGCGTACAT	ELOVL2	F
GTTGTAGCCTCCTTCCCAAGT	ELOVL2	R
ACTTTGTCAGGGACTATCCTGTG	ENO2	F
TCCCTACATTGGCTGTGAACT	ENO2	R
TGGCTCAACCTCATCTTCAA	G6PC3F	F
AGAAGAGGGGAAGTGGTGAAC	G6PC3R	R
TTTGCAATATGACTTTGGAGGA	GADD45A	F
CATCCCCACCTTATCCAT	GADD45A	R
GAGGATGCTGCTGCCAAG	GAP43	F
GGCACTTTCCTTAGGTTTGGT	GAP43	R
TTTTCAAGAAAGCAGGATGGA	GATM	F
TGGAAAGCCATTTGGATGA	GATM	R

GATGGGGGAGTTGGGTGT	GCDH	F
CATAGGCCACAGACGAAACC	GCDH	R
CCGGATACTCACGCCAGA	GDF15	F
AGAGATACGCAGGTGCAGGT	GDF15	R
TGGACCTTCGTCAGTTTGG	GPM6A	F
TCAAGAAATTCTCAGAGACAGTACAAA	GPM6A	R
CCATGGATGTGGTCTACGC	HIST1H4J	F
TAGAAAGGGACGCTCAACCA	HIST1H4J	R
TCCCCTGCCACCAGACTA	HK2	F
TGGACTTGAATCCCTTGGTC	HK2	R
CGATTCAATGACCCTTCTGG	HMMR	F
AGGATACTGGTCCTTTCAATACTTCT	HMMR	R
CGTGGACCACCTGACCTT	HPDL	F
GGAACCAGCGCAAAAGTG	HPDL	R
GAATCCTGAATCGAGCTGAGA	hRARA	F
GGGCCATGTCCTGTGATG	hRARA	R
TCACCAGCCACATCTACCAG	JMJD2B	F
GATGTCCCCACGCTTCAC	JMJD2B	R
GAGGAATCCTGGAGCACAGA	KIAA1712	F
GCAAGATAGGTTCACAAATCAGG	KIAA1712	R
TTCATGTGCAAGTTCGTCAAC	KISS1R	F
CACACTCATGGCGGTCAG	KISS1R	R
GACGGAGTACACGGAGCAG	LASS2	F
CGTTCCCACCAGAAGTAATCA	LASS2	R
CTCCCGAAGAACCCTCTTTC	LRP8	F
GCTTAATGCCACTCGCTTG	LRP8	R
CTACGGCACCTGGTTTGG	LSS	F
CCTCTGCACAGGCAGTCC	LSS	R
CCTGTGTTAAGCGGAAAACC	MAP2	F
AGAGACTTTGTCCTTTGCCTGT	MAP2	R
GCACATTCCTTTTCACCTCAG	MAT2A	F
CTGCTGAAGGTGGGCATC	MAT2A	R
GCGTTACTTAGGCAAAGGTGT	mENO2	F
ATCCTGCTGTTGATGTGGTCC	mENO2	R
AGATGGTGTCAAGCCGGAAG	mGAP43	F
TTTTGGTCGCAGCCTTATGAG	mGAP43	R
CTCGCTCTATCTCTGCTCGTG	mNPY	F
GGCTGGATCTCTTGCCATATCT	mNPY	R
AGACACGCAGACGGGTTG	mRARA	F
GAGGATGCCACTCCCAGA	mRARA	R
TTGTGCTTTTAAACCCAAAGC	MRPL35	F
TATTCAGGGGCCGTAGGATT	MRPL35	R
CCTCTAAAGTTCTTGGATAAAGCAA	MRPL40	F

GCTCTCCTCTCAGTCTCCTCAA	MRPL40	R
TCACTCAGGAAGAATACCATTTTG	MRPS14	F
CCGATTTCTGATTCTAACAGGAC	MRPS14	R
GGCACTCGGAGCTTCTACA	MRPS28	F
GATGCAAAGGATTCCACATTTT	MRPS28	R
GTCCACCGGGTATGGTTCT	MSTO1	F
AACACTGGGATGCTCTCCAC	MSTO1	R
CCAAGGTTCAATTGGACGGC	mTH	F
GGGCATCCTCGATGAGACTC	mTH	R
CCACAAGGCCCTCAGTACC	MYCN	F
CCTCTTCATCATCTTCATCATCTG	MYCN	R
AGGACATCACCGAAGACAGC	NDUFAF3	F
CCCACCACCACGATCTCTAT	NDUFAF3	R
TCTCAGCGCTCCCATGAT	NLN	F
AATCCTGGAACCACCAACTCT	NLN	R
TCCTAGCTGAATGCTATAACCTCTG	NTRK2	F
GGCATCCTTCAGGGTCTTC	NTRK2	R
CACTTCGGCTGCAGAGTTTT	PLOR3G	F
AGTGGGCAAATTCTGAAAGG	PLOR3G	R
CCGATCACTTCTTTTCTTGAT	QTRTD1	F
CCACCTTCAATCACTCCAATG	QTRTD1	R
AATTGTGCGGAAATATCTAGTATCAG	RAB3IP	F
CCAGCTGTGACTCCAGAGGT	RAB3IP	R
GAATGCAGGAAAGAGATCGAA	RANBP1	F
TCTCCTCAGCATCCTCCTTG	RANBP1	R
AGTAGGTGCTTGGCGGTTT	RFC3	F
CACAGTAGATAACACGTGGCAA	RFC3	R
TTTTTCCTTGTGGTGTGAGTGT	RPL27A	F
CCCAATGCACACAGGATGTA	RPL27A	R
CTGTCTCAAGGGGTGATTGC	SKP2	F
TTCGATAGGTCCATGTGCTG	SKP2	R
CATGAGTCTCCGGAAGCAG	SQLE	F
ACAACACCTTCAATAAACTTTGCAT	SQLE	R
ACTATAGCAAACCTCACGGGAAGA	ST18	F
GAGAGCTCACTGGGTCTTTCTCT	ST18	R
AAGCCTCAGCAGTTCTTTGG	TAC1	F
TCTGGCCATGTCCATAAAGAG	TAC1	R
TGCACAGGAGCCAAGAGTGAA	TBP	F
TGCAGACCCTGGACCAACTGTA	TBP	R
ACTACTACGCCAAGGAGGTAC	TGFB1	F
TGCTTGAACCTTGTCATAGATTTTCG	TGFB1	R
GCCAAGGACAAGCTCAGG	TH	F
AGCGTGTACGGGTCTGAACT	TH	R

CCGGACTCAGCTGCAAAC	TRIL4	F
TTGCATTTCTGTATAAACTGTTTCTC	TRIL4	R
GCTCACTCAAGGATCAGTTGG	TSFM	F
CCATGCAGCTCGTTTAAGAA	TSFM	R
GACGTGGATGAAGAATAGCTCTG	TSHZ2	F
CGAAGAAGGGTTCAGTGTGAG	TSHZ2	R
CCAGATCCCCGTGTATGACT	UCK2	F
ACGTCTGCGGGATAGACAGT	UCK2	R
TGAAAGCCAACCTCATGACA	UCP2	F
CGATGACAGTGGTGCAGAA	UCP2	R

ChIP PCR Primer Sequence	Gene symbol	F/R
AGCCACGAGGTCTTGATTG	MIR17HG	F
AGCAATCACCGACTCCACT	MIR17HG	R

Materials and Methods

The individual siRNA target sequences from the pool for validation

KDM2B-01 (5' G.C.A.A.U.A.A.G.G.U.C.A.C.U.G.A.U.C.A.U.U 3'),

KDM5C-01 (5' G.A.G.C.G.G.A.G.G.U.U.U.C.C.U.A.A.U.A.U.U 3')

KDM2B-02 (5' G.A.C.C.U.C.A.G.C.U.G.G.A.C.C.A.A.U.A.U.U 3')

KDM5C-02 (5' G.U.G.G.A.C.A.A.C.U.U.C.A.G.G.U.U.U.A.U.U 3')

KDM4B-01 (5' G.G.A.A.G.A.A.C.C.U.C.A.C.C.U.U.U.G.U.U.U 3')

KDM4B-05 (5' G.G.G.A.A.U.U.C.A.U.G.A.U.C.A.C.A.U.U.U.U 3')

KDM4D-01 (5' G.G.A.A.G.A.A.C.C.G.C.A.U.C.U.A.U.A.A.U.U 3')

KDM4D-02 (5' A.G.A.G.A.G.A.C.C.U.A.U.G.A.U.A.A.U.A.U.U 3')

KDM4E-01 (5' C.U.G.G.A.G.A.G.A.U.G.A.U.A.U.A.G.U.A.U.U 3')

KDM4E-03 (5' C.U.A.G.U.A.A.U.C.U.C.C.C.U.G.A.U.G.U.U.U 3')

KDM6B-01 (5' G.G.A.A.U.G.A.G.G.U.G.A.A.G.A.A.C.G.U.U.U 3')

KDM6B-02 (5' G.G.A.G.A.C.C.U.C.G.U.G.U.G.G.A.U.U.A.U.U 3')

JMJD6-01 (5' G.A.A.C.U.G.G.G.A.U.U.C.A.C.A.U.C.G.A.U.U 3')

JMJD6-02 (5' G.G.A.U.A.A.C.G.A.U.G.G.C.U.A.C.U.C.A.U.U 3')

C14ORF169-01 (5' G.C.G.A.A.G.A.A.C.C.G.C.U.U.U.C.A.U.G.U.U 3')

C14ORF169-02 (5' C.C.C.G.A.G.A.C.U.U.C.A.U.G.G.A.U.U.A.U.U 3')

PHF2-01 (5' G.C.A.A.G.C.G.C.C.U.G.A.C.G.U.C.A.A.G.U.U 3')

PHF2-02 (5' A.G.G.A.G.U.U.U.G.U.G.G.A.C.U.A.U.U.A.U.U 3')

MYCN knockdown target sequences (purchased from Origene) were as follows:

siMYCN#1, ACGCUGAUACAUAACUAAAUUUGAA; siMYCN#2, 5-
AGUUCAUACCUAAGUACUGUAAUAA-3.

High Content Method for H3K9me3 quantification

1000 U2OS-KDM4B expressing cells in 25 µl of media were plated into each well of a poly-D-lysine coated Perkin Elmer 384-well View plates (Perkin Elmer 6007710) with a Thermo Scientific Wellmate. The cells were then grown for 18 hours overnight before they were drugged using a VP scientific pintool with S100 pins. The cells were then treated with compound for a twenty-four hours. Following treatment, the cells were fixed with 4% formaldehyde for 20 minutes at 37°C and permeabilized with 0.1% Triton-X 100 for 15 minutes at 25°C. Fixative was removed and each well washed with PBS. Cells were blocked using 1% BSA in PBS for 1 hour at 25°C. The primary antibody against trimethyl-histone H3 at Lys9 (Millipore 07-442) was used at 1/400 dilution in 1% BSA in

PBS. This mixture was added to each well before incubation overnight at 4°C. Each well was then washed 3 times with PBS using a Biotek plate washer, and incubated for 1 hour at 25°C with a solution containing 1/400 goat α -rabbit-Alexa-488 (Cell Signaling 4412S) and 1 μ M Hoechst 34580 to detect nuclear material (H21486 Molecular Probes.) Two images were captured of each well at 10X using a GE Healthcare InCell 6000 at 405 to detect nuclear staining and 488 nm to detect H3K9me3. The number of nuclear objects in each well, as detected through Hoechst staining, was compared to the number of cells in each well expressing a minimum amount of H3K9me3 as determined by Alexa-488 fluorescence (1.5 million counts total intensity), to identify the percentage of cells in each considered “H3K9me3 Positive.” Averages shown are the result of eight replicate measurements per data point.

Western Blotting

Antibodies H3K9me2 (4658), H3K9me1 (9538), H3K4me3 (9751), H3K4me2 (9725), H3K27me3 (9733), H3K27me2 (9728), H3K36me3 (9763), H3K36me2 (2901), H3K79me3 (4260), H3K79me2 (5427), Histone H3 (9715) were purchased from Cell Signaling. H3K9me3 (07-523), H3K9me2 (07-441), H3K9me1 (107-450), Phosphorylated H2AX (05-636), Acetyl H3 (06-599) were purchased from Millipore. KDM4B (A301-478A), KDM4C (A300-885A), KDM6A (A302-374A), KDM5A (A300-897A) and PHF8 (A301-772A) were purchased from Bethyl Laboratories. β -actin (A1978) antibody was purchased from Sigma. Anti-HA (3F10) antibody was purchased from Roche.

ENCODE data analysis

BigWig files for ChIP-seq data of H3K9me3, Myc and KDM4A from human embryonic stem cells were downloaded from UCSC/ENCODE. Coverage at TSS +/- 2500bp of RefSeq genes was generated in 100 bins for each mark and the combined data were clustered using R.